nature portfolio

Kai M. Thormann

Corresponding author(s): Tim Rick

Last updated by author(s): Jan 19, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

o.			
St	at	ıstı	$1 \cap S$

101	all statistical allalyses, commit that the following items are present in the figure regend, table regend, main text, or interious section.
n/a	Confirmed
	\square The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	A description of all covariates tested
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection BacStalk version 1.8 was used to collect fluorescence data of individual cells

Data analysis Rstudio with R 3.6.3

ggplot2

Graph Pad Prism 5

Blitz Pro

MicroCal Analysis (OriginLab)

MeroX (v2.0)

The PyMOL Molecular Graphics System, Version 2.0 Schrödinger

SMTracker 2.0

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about <u>availability of data</u>

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

	cions on data availability. The raw data of MS-analysis is available as supplemental excel file. For biolayer interference experiments, the raw data emental file of the full report from the BlitzPro software.
Field-spe	ecific reporting
Please select the o	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of	the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scier	nces study design
All studies must dis	sclose on these points even when the disclosure is negative.
Sample size	No sample size calculation was applied.
Data exclusions	No data was excluded
Replication	All data was collected, when possible, in triplicates. When this was not possible (e.g. HDX-MS), the results were verified by additional experiments in replicates accordingly.
Randomization	Not relevant to this publication
Blinding	Not relevant to this publication
Reportin	g for specific materials, systems and methods
We require informati	ion from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,

system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems	Methods
n/a Involved in the study	n/a Involved in the study
Antibodies	ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and archaeology	MRI-based neuroimaging
Animals and other organisms	
Human research participants	
Clinical data	
Dual use research of concern	

Antibodies

Antibodies used	anti-GFP (from mouse IgG1x; Roche: 11814460001) anti-FLAG (monoclonal anti-FLAG M2-peroxidase from mouse, Sigma-Aldrich, A3562.
Validation	Each Western Immunoblot using one of the two antibodies contained a negative control of a same strain not producing a tagged protein of interest.